[Behaviour of serum CPK curves in acute myocardial infarction treated with digitalis, verapamil and combined verapamil-digitalis (author's transl)].
In order to compare the effectiveness of different therapeutic regimens in reducing infarct size serial determinations of CPK activity (at 4 hourly intervals in the first 48 hours from the admission to CCU, at the 72th and at 120th hours) were performed in 100 patients with transmural AMI (53 anterior and 47 inferior) with no obvious evidence of LV failure and basal CPK levels lower than 50 U/L. 20 patients (control group) have been treated with glucose-insulin-potassium (GIK). 20 patients have been treated with GIK plus Verapamil (GIK + V). Verapamil was administered at the dose of 50 mg in continuous drip. 20 patients received GIK plus digoxin at the dose of 0.25 mg b.i.d. (GIK + D). 40 patients received GIK, Verapamil and digoxin at the above doses (GIK + V + D). Different values of CKr and infarct size (IS.) show a statistically significant difference between the various regimens, which is more evident if we consider the whole series. Infarct size was greater in patients treated with digoxin with respect to controls, while it was smaller in patients treated with Verapamil. Combined Verapamil-digoxin therapy is associated to an enzymatic behaviour not different from controls. Authors emphasize that in uncomplicated AMI digoxin causes an increase in infarct size while Verapamil reduces significantly it. Association of Verapamil allows the use of digoxin, if clinically justified, without increase in infarct size.
D000328:Adult; D000368:Aged; D004796:Clinical Enzyme Tests; D003402:Creatine Kinase / Q000097:blood*; D004077:Digoxin / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D011188:Potassium / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use*
D007328:Insulin; D004077:Digoxin; D014700:Verapamil; D003402:Creatine Kinase; D005947:Glucose; D011188:Potassium
Comportamento della curva della creatinfosfochinasi sierica nell'infarto acuto del miocardio trattato con digitale, verapamil e l'associazione verapamil-digitale.